Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Neuroscience"
DOI: 10.1016/j.jocn.2017.06.070
Abstract: Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous… read more here.
Keywords: therapy; bevacizumab; progression bev; bev ... See more keywords